search
Back to results

Oro-gastro-intestinal Digestion of Emulsified Fat

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
administration of fat (sunflower oil), emulsified
Insertion of nasoduodenal tube
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, fat, appetite, digestion

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Signed informed consent form
  2. Sex: male or female
  3. Age: 18-55 years
  4. Body Mass Index (BMI): 18-29 kg/m2
  5. Based on medical history and previous examination, no gastrointestinal complaints can be defined.

Exclusion Criteria:

  1. Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/-connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/-psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol
  2. Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit
  3. Use of psychotropic drugs, including: benzodiazepines. Concomitant medication that can increase gastric pH (e.g. antacids, proton pump inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists), or alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepressants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g., loperamide, chemical/osmotic/bulk laxatives) or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids), except oral contraceptives
  4. Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion
  5. Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment
  6. Score > 9 on Factor 1 (dietary restrained) of the Dutch translation of the Three Factor eating Questionnaire (TFEQ) [17]
  7. Blood donations less than three months previous to study enrollment, and for three months following participation
  8. One or more of the following dietary habits: medically prescribed diets, weight reduction diets, or vegetarian/macrobiotic/biologically dynamic food habits. Administration of investigational drugs in the 180 days prior to the study
  9. Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
  10. Premenstrual syndrome, dieting (medically prescribed, vegetarian, diabetic, biological dynamic)
  11. Excessive alcohol consumption (>20 alcoholic consumptions per week)
  12. Smoking
  13. Self-admitted HIV-positive state

Sites / Locations

  • Maastricht University Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

emulsified fat, orally

intragastric administration of fat

intraduodenal administration of fat

intragastric, non-emulsified fat

Arm Description

At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80

At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically

At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally

At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically

Outcomes

Primary Outcome Measures

Appearance of free fatty acids in the duodenum
The appearance of free fatty acids in the duodenum will be assessed during the 180 min following ingestion of the test product.

Secondary Outcome Measures

Colloidal stability of fat
Droplet size, flocculation, aggregation, coalescence) in samples from the oral, gastric and duodenal compartment will be determined during the 180 min following ingestion of the test product.

Full Information

First Posted
November 14, 2011
Last Updated
October 24, 2012
Sponsor
Maastricht University Medical Center
Collaborators
Top Institute Food and Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT01478750
Brief Title
Oro-gastro-intestinal Digestion of Emulsified Fat
Official Title
Oro-gastro-intestinal Digestion of Emulsified Fat and How This Digestion Relates to Colloidal Stability and Physiological Responses
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Top Institute Food and Nutrition

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Interaction of fat with the mouth, stomach and intestine will trigger physiological responses that will impact on the digestion, gut transit time and absorption of fat. These responses will also influence and contribute to regulation of food intake and satiety. No systematic research on understanding how the physiological-chemical properties of food affect the digestion and absorption of lipids has been carried out previously. Studies have shown that the release of free fatty acids triggers the fat-related responses. The investigators hypothesize that the release of fatty acids depends on the colloidal state of the fat, which changes progressively due to the pH changes and enzyme activities in the mouth, stomach and intestine.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, fat, appetite, digestion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
emulsified fat, orally
Arm Type
Experimental
Arm Description
At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
Arm Title
intragastric administration of fat
Arm Type
Experimental
Arm Description
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
Arm Title
intraduodenal administration of fat
Arm Type
Experimental
Arm Description
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
Arm Title
intragastric, non-emulsified fat
Arm Type
Experimental
Arm Description
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
Intervention Type
Dietary Supplement
Intervention Name(s)
administration of fat (sunflower oil), emulsified
Intervention Description
40 ml sunflower oil, in the presence of the emulsifier tween-80.
Intervention Type
Procedure
Intervention Name(s)
Insertion of nasoduodenal tube
Other Intervention Name(s)
nasoduodenal intubation, nasoduodenal catheter
Intervention Description
A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
Primary Outcome Measure Information:
Title
Appearance of free fatty acids in the duodenum
Description
The appearance of free fatty acids in the duodenum will be assessed during the 180 min following ingestion of the test product.
Time Frame
In the first 180 min after administration of test product
Secondary Outcome Measure Information:
Title
Colloidal stability of fat
Description
Droplet size, flocculation, aggregation, coalescence) in samples from the oral, gastric and duodenal compartment will be determined during the 180 min following ingestion of the test product.
Time Frame
In the first 180 min after administration of test product

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed informed consent form Sex: male or female Age: 18-55 years Body Mass Index (BMI): 18-29 kg/m2 Based on medical history and previous examination, no gastrointestinal complaints can be defined. Exclusion Criteria: Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/-connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/-psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit Use of psychotropic drugs, including: benzodiazepines. Concomitant medication that can increase gastric pH (e.g. antacids, proton pump inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists), or alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepressants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g., loperamide, chemical/osmotic/bulk laxatives) or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids), except oral contraceptives Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment Score > 9 on Factor 1 (dietary restrained) of the Dutch translation of the Three Factor eating Questionnaire (TFEQ) [17] Blood donations less than three months previous to study enrollment, and for three months following participation One or more of the following dietary habits: medically prescribed diets, weight reduction diets, or vegetarian/macrobiotic/biologically dynamic food habits. Administration of investigational drugs in the 180 days prior to the study Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator) Premenstrual syndrome, dieting (medically prescribed, vegetarian, diabetic, biological dynamic) Excessive alcohol consumption (>20 alcoholic consumptions per week) Smoking Self-admitted HIV-positive state
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Freddy Troost, PhD
Organizational Affiliation
Maastricht University Medical Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maastricht University Medical Centre
City
Maastricht
ZIP/Postal Code
NL-6200MD
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

Oro-gastro-intestinal Digestion of Emulsified Fat

We'll reach out to this number within 24 hrs